The WISDOM study: a new approach to screening can and should be tested. Read more about The WISDOM study: a new approach to screening can and should be tested.
Cholesterol lowering drug use and breast cancer survival: the Multiethnic Cohort Study Read more about Cholesterol lowering drug use and breast cancer survival: the Multiethnic Cohort Study
Cholesterol lowering drug use and breast cancer survival: the Multiethnic Cohort Study. Read more about Cholesterol lowering drug use and breast cancer survival: the Multiethnic Cohort Study.
Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer. Read more about Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer.
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer. Read more about Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Read more about Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer. Read more about Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer.
Relationship between body mass index and malignancy rates of MRI-guided breast biopsies: impact of clinicodemographic factors. Read more about Relationship between body mass index and malignancy rates of MRI-guided breast biopsies: impact of clinicodemographic factors.
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. Read more about Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry.
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer. Read more about The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.
